TREATMENT OF LATE-ONSET SYNDROMES SECONDARY TO NEUROLEPTICS

Remission rates for late onset syndromes, a serious and disabling side effect of dopamine receptor blocking agents, are low overall. An accurate phenomenological classification of these syndromes is needed to tailor treatment. The recommended treatment options have a low level of evidence. Clozapine has proven to be effective in clinical practice, particularly in cases of resistant schizophrenia and late onset syndrome. Other therapeutic alternatives seem promising.

Autorentext

El Dr. Hanen BEN AMMAR es psiquiatra y profesor de la Facultad de Medicina de Túnez, Universidad de Túnez El Manar, graduado en Neuropsicofarmacología.